First-in-Canada RNA trial for rare ataxia launches at The Neuro
The Neuro is leading a groundbreaking clinical trial testing an RNA-based therapy for Spinocerebellar Ataxia Type 2 (SCA2), with the potential to halt or reverse disease progression.
Day: March 10, 2025